Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience
Purpose. We sought to evaluate our experience using yttrium-90 (90Y) resin microsphere hepatic radioembolization as salvage therapy for liver-dominant metastatic colorectal cancer (mCRC). Methods. A retrospective review of consecutive patients with unresectable mCRC who were treated with 90Y after f...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | International Journal of Surgical Oncology |
Online Access: | http://dx.doi.org/10.1155/2011/571261 |
id |
doaj-2f282c529f6e4d899757b35e8687721b |
---|---|
record_format |
Article |
spelling |
doaj-2f282c529f6e4d899757b35e8687721b2020-11-24T22:25:19ZengHindawi LimitedInternational Journal of Surgical Oncology2090-14022090-14102011-01-01201110.1155/2011/571261571261Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution ExperienceGary W. Nace0Jennifer L. Steel1Nikhil Amesur2Albert Zajko3Bryon E. Nastasi4Judith Joyce5Michael Sheetz6T. Clark Gamblin7Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USADepartment of Surgery, Medical College of Wisconsin, Milwaukee, WI 53226-3596, USAPurpose. We sought to evaluate our experience using yttrium-90 (90Y) resin microsphere hepatic radioembolization as salvage therapy for liver-dominant metastatic colorectal cancer (mCRC). Methods. A retrospective review of consecutive patients with unresectable mCRC who were treated with 90Y after failing first and second line systemic chemotherapy. Demographics, treatment dose, biochemical and radiographic response, toxicities, and survival were examined. Results. Fifty-one patients underwent 90Y treatments of which 69% were male. All patients had previously undergone extensive chemotherapy, 31% had undergone previous liver-directed therapy and 24% had a prior liver resection. Using RECIST criteria, either stable disease or a partial response was seen in 77% of patients. Overall median survival from the time of first 90Y treatment was 10.2 months (95% CI = 7.5–13.0). The absence of extrahepatic disease at the time of treatment with 90Y was associated with an improved survival, median survival of 17.0 months (95% CI = 6.4–27.6), compared to those with extrahepatic disease at the time of treatment with 90Y, 6.7 months (95% CI = 2.7–10.6 Conclusion: 90Y therapy is a safe locoregional therapy that provides an important therapeutic option to patients who have failed first and second line chemotherapy and have adequate liver function and performance status.http://dx.doi.org/10.1155/2011/571261 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gary W. Nace Jennifer L. Steel Nikhil Amesur Albert Zajko Bryon E. Nastasi Judith Joyce Michael Sheetz T. Clark Gamblin |
spellingShingle |
Gary W. Nace Jennifer L. Steel Nikhil Amesur Albert Zajko Bryon E. Nastasi Judith Joyce Michael Sheetz T. Clark Gamblin Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience International Journal of Surgical Oncology |
author_facet |
Gary W. Nace Jennifer L. Steel Nikhil Amesur Albert Zajko Bryon E. Nastasi Judith Joyce Michael Sheetz T. Clark Gamblin |
author_sort |
Gary W. Nace |
title |
Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience |
title_short |
Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience |
title_full |
Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience |
title_fullStr |
Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience |
title_full_unstemmed |
Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience |
title_sort |
yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience |
publisher |
Hindawi Limited |
series |
International Journal of Surgical Oncology |
issn |
2090-1402 2090-1410 |
publishDate |
2011-01-01 |
description |
Purpose. We sought to evaluate our experience using yttrium-90 (90Y) resin microsphere hepatic radioembolization as salvage therapy for liver-dominant metastatic colorectal cancer (mCRC). Methods. A retrospective review of consecutive patients with unresectable mCRC who were treated with 90Y after failing first and second line systemic chemotherapy. Demographics, treatment dose, biochemical and radiographic response, toxicities, and survival were examined. Results. Fifty-one patients underwent 90Y treatments of which 69% were male. All patients had previously undergone extensive chemotherapy, 31% had undergone previous liver-directed therapy and 24% had a prior liver resection. Using RECIST criteria, either stable disease or a partial response was seen in 77% of patients. Overall median survival from the time of first 90Y treatment was 10.2 months (95% CI = 7.5–13.0). The absence of extrahepatic disease at the time of treatment with 90Y was associated with an improved survival, median survival of 17.0 months (95% CI = 6.4–27.6), compared to those with extrahepatic disease at the time of treatment with 90Y, 6.7 months (95% CI = 2.7–10.6 Conclusion: 90Y therapy is a safe locoregional therapy that provides an important therapeutic option to patients who have failed first and second line chemotherapy and have adequate liver function and performance status. |
url |
http://dx.doi.org/10.1155/2011/571261 |
work_keys_str_mv |
AT garywnace yttrium90radioembolizationforcolorectalcancerlivermetastasesasingleinstitutionexperience AT jenniferlsteel yttrium90radioembolizationforcolorectalcancerlivermetastasesasingleinstitutionexperience AT nikhilamesur yttrium90radioembolizationforcolorectalcancerlivermetastasesasingleinstitutionexperience AT albertzajko yttrium90radioembolizationforcolorectalcancerlivermetastasesasingleinstitutionexperience AT bryonenastasi yttrium90radioembolizationforcolorectalcancerlivermetastasesasingleinstitutionexperience AT judithjoyce yttrium90radioembolizationforcolorectalcancerlivermetastasesasingleinstitutionexperience AT michaelsheetz yttrium90radioembolizationforcolorectalcancerlivermetastasesasingleinstitutionexperience AT tclarkgamblin yttrium90radioembolizationforcolorectalcancerlivermetastasesasingleinstitutionexperience |
_version_ |
1725758306297839616 |